[1. Chan GW, Ungvari GS, Shek DT, Leung Dagger JJ.Hospital and community-based care for patients with chronic schizophrenia in Hong Kong- quality of life and its correlates. Soc Psychiatry Psychiatr Epidemiol 2003; 38(4): 196-203.10.1007/s00127-003-0616-512664230]Search in Google Scholar
[2. Salome F, Petitjean F, Germain C, Demant JC. The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients’ expectations.]Search in Google Scholar
[A comparative study. Encephale 2004; 30(1): 60-8.10.1080/00963402.2004.11460817]Search in Google Scholar
[3. Rossler W, Salize HJ, Cucchiaro G, Reinhard I, Kernig C.Does the place of treatment influence the quality of life of schizophrenics? Acta Psychiatr Scand. 1999; 100(2): 142-8.10.1111/j.1600-0447.1999.tb10835.x10480200]Search in Google Scholar
[4. Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. Curr Med Res Opin. 2010; 26(4): 787-801.10.1185/0300799090357695320121655]Search in Google Scholar
[5. Kane JM, Kim E, Kan HJ, Guo Z, Bates JA, Whitehead R, Pikalov A. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Appl Health Econ Health Policy. 2009; 7(2): 109-19.10.1007/BF0325614519731968]Search in Google Scholar
[6. Bebbington PE, Angermeyer M, Azorin JM, Marwaha S, Marteau F, Toumi M. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia.Acta Psychiatr Scand Suppl. 2009; 438: 22-8.10.1111/j.1600-0447.2008.01310.x19132963]Search in Google Scholar
[7. www.who.int]Search in Google Scholar
[8. Mas-Exposito L, Amador-Campos JA, Gomez-Benito J, Lalucat-Jo L. The World Health Organization Quality of Life Scale Brief Version: a validation study in patients with schizophrenia. Qual Life Res. 2011; 20(7): 1079-89.10.1007/s11136-011-9847-121290191]Search in Google Scholar
[9. World Health Organization. ICD-10 Chapter V. Diagnostic Criteria for Research. Genova: WHO, 1993.]Search in Google Scholar
[10. Zaghdoudi L, Homri W, Belaid S, Ben Bechir M, Labbane R. Quality of life of patient with schizophrenia treated by conventional and atypical neuroleptics. Tunis Med. 2009; 87(9): 593-8.]Search in Google Scholar
[11. Zhang PL, Santos JM, Newcomer J, Pelfrey BA, Johnson MC. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res. 2004; 71(1): 137-44. 10.1016/j.schres.2003.11.00515374581]Search in Google Scholar
[12. Midori Fujikawa, Takashi Togo, Asuka Yoshimi et al Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients. Progress in Neuro Psychopharmacology & Biological Psychiatry 2008; 32: 755-760.10.1016/j.pnpbp.2007.12.00218226436]Search in Google Scholar
[13. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003; 54: 719-23.10.1176/appi.ps.54.5.71912719504]Search in Google Scholar
[14. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A,Wagner T, et al Prediction of remission as a combination of symptomatic and functionalremission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006; 67: 1690-7.10.4088/JCP.v67n110417196047]Search in Google Scholar
[15. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents. Am J Psychiatry 2002; 159: 103-8.10.1176/appi.ajp.159.1.10311772697]Search in Google Scholar
[16. Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane S et al The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psichiatry 2003; 18(5): 432-40.10.1002/gps.86212766921]Search in Google Scholar
[17. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al Randomized controlled trial of the effect on quality of life of second- vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUt- LASS 1). Arch Gen Psychiatry 2006; 63: 1079-87.10.1001/archpsyc.63.10.107917015810]Search in Google Scholar
[18. Loffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients’ subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36: 105-12.10.1055/s-2003-3998512806568]Search in Google Scholar
[19. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW.Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004; 65: 354-60. 10.4088/JCP.v65n0311]Search in Google Scholar